Want to join the conversation?
$BIIB 2Q15 Call: In the US total market growth in switch rates remained lower than original expectations. Expects AVONEX and PLEGRIDY will continue to play an important role. TYSABRI demonstrated positive patient growth in 2Q15. ALPROLIX and ELOCTATE continue to grow market share in the US; strong initial uptake in Japan.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)